(Q45942815)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19571807%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19571807%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19571807%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Raymond Siu-Ming Wong

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19571807%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

K K N Tsui

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19571807%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

G Cheng

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19571807%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

English

0 references

publication date

1 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19571807%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19571807%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

86

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19571807%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19571807%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

540-547

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19571807%20AND%20SRC:MED&resulttype=core&format=json

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Interindividual variability in sensitivity to warfarin--Nature or nurture?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Factors affecting the maintenance dose of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Equal proportion of adult male and female homozygous for the 677C ? T mutation in the methylenetetrahydrofolate reductase polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

A decision chart for assessing and improving the transferability of economic evaluation results between countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Management of Chinese patients on warfarin therapy in two models of anticoagulation service - a prospective randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Death and disability from warfarin-associated intracranial and extracranial hemorrhages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Effect of aspirin and warfarin on early survival after intracerebral haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

The cost-effectiveness of different management strategies for patients on chronic warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

21 January 2018

When Drugs Don??t Work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

7 January 2021

Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

7 January 2021

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

7 January 2021

Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

7 January 2021

The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

7 January 2021

CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

7 January 2021

Health-care systems and pharmacoeconomic research in Asia-Pacific region

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

7 January 2021

Cost-effectiveness of two models of management for patients on chronic warfarin therapy--a Markov model analysis.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.104

7 January 2021